Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.

Additional investment and resources will accelerate Biocomposites' international expansion and innovation in products for use in infection management HELLERUP, Denmark, LONDON and KEELE ...

HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to make an investment ...

Novo Nordisk also reported the acquisition of three manufacturing sites from Novo Holdings A/S following the finalization of Novo Holdings' acquisition of Catalent, Inc. - a global contract ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...

In December, Novo Holdings, an investment foundation of Novo Nordisk, acquired three manufacturing sites in Catalent to expand its production capacity. CEO Lars Fruergaard Jørgensen commented ...

Meanwhile, thanks to the completion of Novo Holdings’ $16.5 billion Catalent acquisition in December, Novo Nordisk has purchased three of the CDMO’s production sites, bringing its total number ...

In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.